Statistics from Altmetric.com
Intravitreal Ranibizumab (Lucentis) monotherapy is currently the standard of care for neovascular age-related macular degeneration (AMD), supported by well-conducted clinical trials and non-randomised studies.1–4 Visual and anatomical outcomes are definitely better than Verteporfin Photodynamic therapy (PDT), but the treatment comes at a cost.5 The current goal of anti-vascular endothelial growth factor (VEGF) agents is to stabilise and/or improve vision. The natural history of untreated disease leads to irreversible visual loss in majority of patients.6 Current evidence-based literature is lacking for patients with “active, symptomatic” neovascular AMD with centre involvement and visual acuity better than 6/12 (20/40) at presentation. We present 12-month outcomes for neovascular AMD patients treated with Lucentis and presenting baseline visual acuity better than (6/12).
Fourteen eyes of 14 patients with neovascular AMD were …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.